30 June 2023 - Shionogi today announced that Eddingpharm has received approval for Mulpleta (lusutrombopag), a once daily, orally administered, small molecule thrombopoietin receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure from the Center for Drug Evaluation, NMPA.

Shionogi has concluded a license agreement with Edding to out-license the exclusive marketing rights of Mulpleta in Mainland China, Hong Kong and Macau. Based on this license agreement, Shionogi plan to supply the product to Edding and receive an upfront payment as well as milestone payments according to post-launch sales periods.

Read Shionogi press release